SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression
Cancer Letters · 2024-08 · 598 · 217109
DOI: 10.1016/j.canlet.2024.217109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Keyu Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Key Laboratory of Carcinogenesis and Translational Research (Mini…. Hauptthemen laut MEDLINE: Gemcitabine, Deoxycytidine, Sirtuins, Pancreatic Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Gemcitabine serves as a first-line chemotherapeutic treatment for pancreatic cancer (PC), but it is prone to rapid drug resistance. Increasing the sensitivity of PC to gemcitabine has long been a focus of research. Fasting interventions may augment the effects of chemotherapy and present new options. SIRT7 is known to link metabolism with various cellular processes through post-translational modifications. We found upregulation of SIRT7 in PC cells is associated with poor prognosis and gemcitabine resistance. Cross-analysis of RNA-seq and ATAC-seq data suggested that GLUT3 might be a downstream target gene of SIRT7. Subsequent investigations demonstrated that SIRT7 directly interacts with the enhancer region of GLUT3 to desuccinylate H3K122. Our group's another study revealed that GLUT3 can transport gemcitabine in breast cancer cells. Here, we found GLUT3 KD reduces the sensitivity of PC cells to gemcitabine, and SIRT7 KD-associated gemcitabine-sensitizing could be reversed by GLUT3 KD. While fasting mimicking induced upregulation of SIRT7 expression in PC cells, knocking down SIRT7 enhanced sensitivity to gemcitabine through upregulating GLUT3 expression. We further confirmed the effect of SIRT7 deficiency on the sensitivity of gemcitabine under fasting conditions using a mouse xenograft model. In summary, our study demonstrates that SIRT7 can regulate GLUT3 expression by binding to its enhancer and altering H3K122 succinylation levels, thus affecting gemcitabine sensitivity in PC cells. Additionally, combining SIRT7 knockdown with fasting may improve the efficacy of gemcitabine. This unveils a novel mechanism by which SIRT7 influences gemcitabine sensitivity in PC and offer innovative strategies for clinical combination therapy with gemcitabine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Health Science Center, Beijing,…
- Department of General Surgery, Peking University First Hospital, Beijing, 100034, China. Electronic address: YangyinmoSCI@bjmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, K., Li, T., Diao, H., Wang, Q., Zhou, X., Huang, Z., Wang, M., Mao, Z., Yang, Y., & Yu, W. (2024). SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression. Cancer Letters, 598, 217109. https://doi.org/10.1016/j.canlet.2024.217109
Vancouver
Chen K, Li T, Diao H, Wang Q, Zhou X, Huang Z, et al. SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression. Cancer Letters. 2024;598:217109. doi:10.1016/j.canlet.2024.217109
BibTeX
@article{Chen2024,
author = {Chen, Keyu and Li, Tiane and Diao, Honglin and Wang, Qikai and Zhou, Xiaojia and Huang, Zhihua and Wang, Mingyue and Mao, Zebin and Yang, Yinmo and Yu, Wenhua},
title = {SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression},
journal = {Cancer Letters},
year = {2024},
volume = {598},
pages = {217109},
doi = {10.1016/j.canlet.2024.217109}
}
EUVIMED